Correction: Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison
Frontiers in Oncology · 29.06.2026 · 16
DOI: 10.3389/fonc.2026.1883614 ↗Kurz gefasst
Korrektur in der Zeitschrift Frontiers in Oncology, online erschienen am 29.06.2026. Verfasst von Luna Del Bono und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Specialization in Hospital Pharmacy, Department of Pharmacy, University of Pisa, Pisa, Italy. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Specialization in Hospital Pharmacy, Department of Pharmacy, University of Pisa, Pisa, Italy.
- Territorial Pharmaceutical Service, Azienda Unità Locale Socio-Sanitaria (ULSS) 8 Berica, Vicenza, Italy.
- Italian Society of Clinical Pharmacy and Therapeutics, Turin, Italy.
- Pharmaceutical Department, Unità Sanitaria Locale (USL) Toscana Centro, Prato, Italy.
- Hospital Pharmacy Unit, Ospedale Guglielmo da Saliceto, Piacenza, Italy.
- Hospital Pharmacy Department, Azienda Ulss 2 Marca Trevigiana, Treviso, Italy.
Zitieren
APA
Del Bono, L., Ossato, A., Gasperoni, L., Vecchia, S., Cancanelli, L., Damuzzo, V., Gori, S., Tessari, R., Sava, T., & Inno, A. (2026). Correction: Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1883614
Vancouver
Del Bono L, Ossato A, Gasperoni L, Vecchia S, Cancanelli L, Damuzzo V, et al. Correction: Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1883614
BibTeX
@article{DelBono2026,
author = {Del Bono, Luna and Ossato, Andrea and Gasperoni, Lorenzo and Vecchia, Stefano and Cancanelli, Luca and Damuzzo, Vera and Gori, Stefania and Tessari, Roberto and Sava, Teodoro and Inno, Alessandro},
title = {Correction: Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1883614}
}
EUVIMED